HealthTech Bio Actives (HTBA) has announced the construction of a new diosmin production plant at its research, development, and manufacturing centre in Murcia, Spain. With an investment of over €6 million, the new plant will enable the company to increase its diosmin production capacity by more than 40%, supporting its sustainable growth plans. For pharmaceutical and nutraceutical manufacturers, this paves the way for further innovation with diosmin – an ingredient that can enhance venous tone and circulation, and address vascular discomfort.
As the world’s largest producer of diosmin, HTBA manufactures diosmin as an active pharmaceutical ingredient (API) for the treatment of chronic cardiovascular disease (CVD), varicose veins, spider veins and haemorrhoids, as well as a food supplement ingredient, DiosVein®, to keep legs healthy. In line with the company’s long-term strategic growth plans, through this investment HTBA continues to strengthen its diosmin innovation and manufacturing capabilities.
Said Alexandre Valls-Coma, Chief Executive Officer: “This latest investment further reinforces HTBA’s standing as an international leader in the production of flavonoids, supporting innovation in the health and wellness sector. By prioritising innovation and sustainable manufacturing, over the last few years the company has entered a period of remarkable growth. This project further strengthens our expansion and competitiveness in a highly regulated and demanding global environment.”
As part of HTBA’s ongoing commitment to zero-waste, the company uses solvent-free manufacturing for its diosmin that yields no remaining organic solvents and ensures compliance with the highest quality standards. The new manufacturing plant will further consolidate HTBA’s position as the only company in the world capable of manufacturing diosmin using water as a solvent, thanks to its patented process that offers more natural, sustainable and safe solutions for consumers. Linked to this approach, HTBA recently received Zero Waste certification, granted by AENOR, verifying that the company valorises at least 90% of the waste it generates, preventing it from ending up in landfill.
Added Ignacio Paco Ferreira, Chief Operations Officer: “We’re always striving to achieve better solutions and processes that improve manufacturing sustainability and efficiency while helping to support health and wellbeing. Our new plant will not only increase production, it will also equip us to improve our operating model through research-driven process innovation, digitalisation, and energy efficiency. With improved and expanded production, we’re gearing up to better meet customer and consumer needs for the long-term, offering consistent, reliable supply as a trusted source of high-quality diosmin for nutraceutical and pharmaceutical applications.”
Earlier this year, the company announced the completion of a previous €25 million investment project to modernise its research, development and manufacturing centre in Spain. The initiative involved the construction of a new state-of-the-art production plant, making HTBA the only company in Europe capable of producing all active forms of vitamin B12, further reinforcing its status as a leader in the industry. For more visit htba.com
(Pictured left to right, front row: Federico Miralles Pérez, General Director of Industry, Energy and Mines in Murcia, Marisa López Aragón, Regional Minister of Enterprise, Employment and Social Economy in Murcia, Alexandre Valls Coma, Chief Executive Officer of HTBA, Mari Carmen Morales, Mayor of Beniel, Ignacio Paco, Chief Operation Officer of HTBA. Pictured left to right, back row: Isabel Canales, Head of Plant Beniel of HTBA, José Antonio García, Beniel City Council member, Susi Hernández, Chief Strategy Officer of HTBA, Alba Rodríguez, Beniel City Council member.)
